IRIS
FACCHINETTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.807
AS - Asia 1.232
EU - Europa 711
SA - Sud America 203
Continente sconosciuto - Info sul continente non disponibili 64
AF - Africa 50
Totale 4.067
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.733
SG - Singapore 508
CN - Cina 239
VN - Vietnam 192
IT - Italia 172
SE - Svezia 162
BR - Brasile 140
IE - Irlanda 132
HK - Hong Kong 98
BD - Bangladesh 71
DE - Germania 51
FR - Francia 43
CA - Canada 39
ZA - Sudafrica 35
NL - Olanda 31
GB - Regno Unito 29
IN - India 26
AT - Austria 23
TR - Turchia 21
ID - Indonesia 18
MX - Messico 16
RU - Federazione Russa 15
AR - Argentina 14
JP - Giappone 13
EC - Ecuador 12
PL - Polonia 10
CO - Colombia 9
BO - Bolivia 7
CL - Cile 7
BE - Belgio 6
PK - Pakistan 6
PY - Paraguay 6
FI - Finlandia 5
UA - Ucraina 5
VE - Venezuela 5
AL - Albania 4
ES - Italia 4
IL - Israele 4
IQ - Iraq 4
NI - Nicaragua 4
PH - Filippine 4
HN - Honduras 3
KE - Kenya 3
MA - Marocco 3
RO - Romania 3
SA - Arabia Saudita 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
CH - Svizzera 2
CI - Costa d'Avorio 2
GR - Grecia 2
JM - Giamaica 2
JO - Giordania 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
NP - Nepal 2
SC - Seychelles 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BG - Bulgaria 1
BZ - Belize 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
GD - Grenada 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
MY - Malesia 1
OM - Oman 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
UY - Uruguay 1
ZM - Zambia 1
Totale 4.006
Salva come PNG Salva come JPEG
Città #
Singapore 290
Ashburn 278
Chandler 195
San Jose 156
Santa Clara 140
Dublin 129
Dallas 111
Council Bluffs 102
Hong Kong 93
New York 65
Ho Chi Minh City 61
Beijing 59
Shanghai 50
Boardman 38
Ann Arbor 35
Hanoi 34
Lauterbourg 32
Los Angeles 32
Johannesburg 30
Princeton 23
Bremen 20
Milan 19
Vienna 19
Buffalo 17
Da Nang 17
Columbus 14
Dearborn 14
Parma 14
Rome 14
Atlanta 13
Des Moines 13
Jakarta 13
Wilmington 11
Chicago 10
Mexico City 10
Munich 10
São Paulo 10
Tokyo 10
Curitiba 9
Montreal 9
Phoenix 9
The Dalles 9
Warsaw 9
Bologna 8
Nanjing 8
Brooklyn 7
Frankfurt am Main 7
Haiphong 7
Izmir 7
London 7
Moscow 7
Pune 7
Quito 7
Toronto 7
Biên Hòa 6
Changsha 6
Houston 6
Rio de Janeiro 6
Amsterdam 5
Brussels 5
Denver 5
Helsinki 5
Nuremberg 5
Washington 5
Ankara 4
Belo Horizonte 4
Boston 4
Busseto 4
Can Tho 4
Cape Town 4
Dhaka 4
Genoa 4
Guangzhou 4
Kunming 4
Nanchang 4
Naples 4
Orem 4
Pavia 4
Tirana 4
Trieste 4
Baghdad 3
Buenos Aires 3
Charlotte 3
Figino 3
Florence 3
Francisco Morato 3
Fremont 3
Grafing 3
Guayaquil 3
Hebei 3
Hải Dương 3
Istanbul 3
Jinan 3
La Paz 3
Managua 3
Manchester 3
Marseille 3
Modena 3
Nanning 3
Newark 3
Totale 2.503
Salva come PNG Salva come JPEG
Nome #
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 217
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 192
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 174
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 165
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 162
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 161
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 161
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 155
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib 150
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient 145
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 144
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 141
Exploring the role of respiratory microbiome in lung cancer: A systematic review 136
Cystic brain metastases and RET fusion in lung cancer 136
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 135
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis 131
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 130
Moving immune checkpoint blockade in thoracic tumors beyond NSCLC 129
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 127
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 127
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 115
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 110
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 105
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer 104
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial 77
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 74
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis 73
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 68
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making 66
ALK fusions turn sixteen in lung cancer: a review on their biology, detection and therapy 65
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC 56
Non-small-cell lung cancer: how to manage BRAF-mutated disease 44
Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P 42
Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era 41
Liquid Biopsy Monitoring in BRAF V600E–Mutated Patients With Non–Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020) 9
Totale 4.067
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.743
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.743
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022117 0 0 0 0 2 3 27 7 9 6 7 56
2022/2023619 81 76 38 56 45 77 23 31 164 6 21 1
2023/2024229 11 19 3 2 17 80 18 17 12 10 10 30
2024/2025645 6 30 35 47 99 94 25 12 88 57 49 103
2025/20261.790 132 91 215 166 298 120 172 65 226 129 103 73
2026/2027414 67 93 107 126 21 0 0 0 0 0 0 0
Totale 4.067